Aspen Pharmacare’s CEO, Stephen Saad, has celebrated the company’s new licensing agreement to enter the rapidly expanding GLP-1 agonist market. He said this milestone marks a “significant coup” for the company, enabling it to prepare for the market by 2026 and capitalise on the anticipated demand for diabetes and obesity treatment solutions. The global GLP-1 market, driven by increased demand…